GlassScriptPhysician profile
Megan M Youngstead
NPI 1346840055
$5,651.58
in general payments reported to CMS, 2019-2025
28 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $1,987 · 2023: $1,780 · 2024: $1,391 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Travel and Lodging: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.63 |
| Travel and Lodging | $506.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,484.98 | 2022-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Nalu Medical, INC. | $700.07 | 2023-2024 | Nalu Neurostimulation System |
| Abbvie INC. | $632.33 | 2022-2025 | |
| Spinal Simplicity, LLC | $587.96 | 2022 | |
| Biotronik Nro, INC. | $558.57 | 2023-2024 | Prospera, Biotronik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.86 | 2022-2025 | Relistor |
| Vertos Medical, INC. | $321.43 | 2023-2024 | Mild Device Kit |
| Nevro Corp. | $245.75 | 2022-2024 | Senza |
| Abbott Laboratories | $241.23 | 2025 | Proclaim |
| Medtronic, INC. | $105.34 | 2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $87.37 | 2022-2023 | Belbuca, Xtampza |
| Novo Nordisk INC | $37.71 | 2021 | |
| Bioventus LLC | $36.95 | 2023-2024 | Durolane, Durolane |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.80 | 2021 | |
| Spr Therapeutics, INC | $27.45 | 2023 | Sprint Pns System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $25.36 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $22.14 | 2024 | |
| Stryker Corporation | $21.23 | 2024 | Mild Device Kit |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.30 | 2021 | |
| Valinor Pharma, LLC | $17.89 | 2024 | Movantik |
| Painteq LLC | $17.70 | 2022 | |
| Depuy Synthes Sales INC. | $16.37 | 2024 | Orthovisc |
| Almatica Pharma LLC | $16.10 | 2023 | Gralise |
| Electronic Waveform Lab, INC. | $15.35 | 2024 | |
| Redhill Biopharma INC. | $15.12 | 2022 | |
| Dexcom, INC. | $14.56 | 2021 | |
| Foundation Fusion Solutions, LLC | $8.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Youngstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.